BioAtla, Inc. (BCAB)
OTCMKTS · Delayed Price · Currency is USD
1.080
-0.610 (-36.09%)
At close: Sep 1, 2026
BioAtla Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue | 8.5 | 2 | 11 | - | - | 0.25 |
Revenue Growth | -22.73% | -81.82% | - | - | - | -41.73% |
Cost of Revenue | 24.56 | 43.07 | 63.1 | 103.73 | 79.35 | 58.27 |
Gross Profit | -16.06 | -41.07 | -52.1 | -103.73 | -79.35 | -58.02 |
Selling, General & Admin | 14.97 | 17.63 | 21.85 | 25.96 | 28.79 | 38.42 |
Operating Expenses | 14.97 | 17.63 | 21.85 | 25.96 | 28.79 | 38.42 |
Operating Income | -31.03 | -58.71 | -73.94 | -129.69 | -108.14 | -96.44 |
Interest Expense | - | - | - | - | - | -0 |
Interest & Investment Income | 0.26 | 0.84 | 3.37 | 6.31 | 1.65 | 0.35 |
Other Non Operating Income (Expenses) | 0.41 | -1.15 | 0.8 | -0.09 | 0.01 | 0 |
EBT Excluding Unusual Items | -30.35 | -59.01 | -69.78 | -123.46 | -106.48 | -96.09 |
Merger & Restructuring Charges | -1.1 | -0.6 | - | - | - | - |
Other Unusual Items | - | - | - | - | - | 0.69 |
Pretax Income | -31.45 | -59.61 | -69.78 | -123.46 | -106.48 | -95.4 |
Earnings From Continuing Operations | -31.45 | -59.61 | -69.78 | -123.46 | -106.48 | -95.4 |
Net Income | -31.45 | -59.61 | -69.78 | -123.46 | -106.48 | -95.4 |
Net Income to Common | -31.45 | -59.61 | -69.78 | -123.46 | -106.48 | -95.4 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 1 | 1 |
Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 1 | 1 |
Shares Change | 28.86% | 21.11% | 1.67% | 22.73% | 12.63% | 310.07% |
EPS (Basic) | -22.73 | -50.66 | -71.83 | -129.21 | -136.77 | -138.02 |
EPS (Diluted) | -22.74 | -50.66 | -71.83 | -129.21 | -136.77 | -138.02 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -23.48 | -48.2 | -71.94 | -104.11 | -90.69 | -63.14 |
Free Cash Flow Per Share | -16.97 | -40.97 | -74.05 | -108.96 | -116.48 | -91.34 |
Gross Margin | -188.92% | - | - | - | - | - |
Operating Margin | -365.00% | -2935.25% | -672.21% | - | - | -38576.00% |
Profit Margin | -370.05% | -2980.35% | -634.33% | - | - | -38160.80% |
Free Cash Flow Margin | -276.26% | -2410.20% | -653.96% | - | - | -25255.20% |
EBITDA | -30.83 | -58.33 | -73.02 | -128.47 | -106.94 | -95.11 |
D&A For EBITDA | 0.2 | 0.37 | 0.93 | 1.22 | 1.2 | 1.33 |
EBIT | -31.03 | -58.71 | -73.94 | -129.69 | -108.14 | -96.44 |